A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors Meeting Abstract


Authors: Drilon, A.; Marwan, F.; Fu, S.; Patel, M. R.; Olszanski, A. J.; Lockhart, A. C.; Liu, S. V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; Patel, R.; Oliver, J. W.; Multani, P. S.; Wang, D.
Abstract Title: A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors
Meeting Title: 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Journal Title: European Journal of Cancer
Volume: 69
Issue: Suppl. 1
Meeting Dates: 2016 Nov 29-Dec 2
Meeting Location: Munich, Germany
ISSN: 0959-8049
Publisher: Elsevier Inc.  
Date Published: 2016-12-01
Start Page: S143
Language: English
ACCESSION: WOS:000390503500419
PROVIDER: wos
DOI: 10.1016/S0959-8049(16)33024-6
Notes: Meeting Abstract: 437 -- 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 29-DEC 02, 2016 -- Munich, GERMANY -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alexander Edward Drilon
    632 Drilon